SARS-CoV-2 Neutralisation Assay Development Kits에는 Spike-Antibody Binding을 측정하기 위한 모든 시약이 포함되어 있으며, 이를 이용하여 Variant RBD-ACE2 Interaction들을 중화시키는 Antibody의 능력을 식별하고 정성적으로 평가하는데 사용할 수 있습니다.
– Kit 구성품 –
1) Negative Control Anti-SARS-CoV-2 Antibody
2) Positive Control Anti-SARS-CoV-2 RBD Antibody
3) Variant SARS-CoV-2 RBD Protein
4) HRP-labelled ACE2 Protein
각각의 Variant의 제품 설명은 아래의 정보들을 참고해 주십시오.
Our SARS-CoV-2 Delta Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.617.2 RBD (L452R, T478). In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:
NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #2 is between 50% and 60% and is therefore positive for the presence of neutralizing antibodies. SARS-CoV-2 serum samples #1 and #3 are >60%, indicating no neutralizing capacity.
Our SARS-CoV-2 Kerala Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.617.1 RBD (E484Q, L452R). In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:
NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum samples #1 and #2 are <50% and therefore positive for the presence of neutralizing antibodies. Serum sample #3 is 60%, indicating no neutralizing capacity.
Our SARS-CoV-2 South African Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.351 RBD (K417N, E484K, N501Y). In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:
NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >60%, indicating that neutralizing antibodies are absent.
Our SARS-CoV-2 Brazilian Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the B.1.1.28 RBD (K417T, E484K, N501Y). In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:
NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >60%, indicating no neutralizing capacity.
Our SARS-CoV-2 UK Variant Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to the N501Y RBD. In-house data shows that SARS-CoV-2-positive patient sera is able to neutralise binding:
NTRL Assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum sample #1 is >50% but <60%, indicating moderate neutralizing capacity.
Our SARS-CoV-2 Neutralisation Assay Development Kit is designed for the qualitative assessment of neutralising antibodies to wild-type SARS-CoV-2. In-house data shows that different SARS-CoV-2-positive patient sera is able to variably neutralise binding:
NTRL assay: Binding rate (B/B0%) for negative samples is ≥ 60%. Binding rate for strongly positive samples is ≤ 50%. Borderline samples, with moderate neutralization, may be assessed with binding rates between 50-60. Negative and positive control antibodies were included. SARS-CoV-2 serum samples #1, #2 and #3 are < 50% and considered strongly positive indicating SARS-CoV-2 neutralizing antibody is present in these samples. Samples #4, #5 and #6 are derived from SARS patient sera, and show binding of >50%, indicating moderate or negative neutralizing capacity.
* 주문 및 견적 문의는 지사/대리점으로 연락 주세요.
- 지사/대리점 안내Opens in a new tab
